Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment

• Published in: Journal of comparative effectiveness research Vol. 7; no. 4; pp. 343 - 356
• Main Authors: Thayer, David, Noda, Christopher, Charalel, Resmi, Mills, Abigail, Chang, Randy, Tao, Yu, Akinwande, Olaguoke
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.04.2018
• Subjects: advanced hepatocellular carcinoma; comparative effectiveness; hazard ratio; liver cancer-specific survival; nonoperative treatment; overall survival; palliation; prognostic prediction; liver cancer-specific survival; prognostic prediction; advanced hepatocellular carcinoma; palliation; nonoperative treatment; comparative effectiveness; hazard ratio; overall survival
• ISSN: 2042-6305; 2042-6313
• DOI: 10.2217/cer-2017-0064

To compare the overall survival (OS) and liver cancer-specific survival of advanced-stage hepatocellular carcinoma (HCC) patients who received transarterial radioembolization (TARE) with those who received nonoperative/interventional treatment (NOT). A total of 12,520 HCC patients from the Surveillance, Epidemiology and End Results database were categorized by treatment with either radioembolization or NOT. Kaplan-Meier and multivariate Cox regression were conducted. The TARE group had both a significantly longer median overall survival than the NOT group (TARE = 9 months; NOT = 2 months; p < 0.0001) and a significantly higher probability of liver cancer-specific survival (hazard ratio = 0.474). TARE appears to provide a significant survival advantage over the NOT population in advanced HCC patients.